David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Eli Lilly‘s experimental Alzheimer’s treatment hit another hurdle with U.S. drug regulators. It pushed out the timeline for potential approval but did not rattle our investment thesis in the company.



Source link